Prescription Opioids: Risk Management and Strategies for Safe Use _ _________________________________
35. The introduction of abuse-deterrent OxyContin has resulted in A) no effect in the rates of OxyContin abuse/addiction. B) decreased rates of OxyContin abuse/addiction and increased rates of heroin abuse/addiction. C) a uniform decrease in abuse/addiction rates of prescription and street opioids. D) decreased rates of OxyContin abuse/addiction and no change in other opioids. 36. The ARCOS system that monitors the flow of controlled substances through the distribution chain is run by the
28. Which of the following is one of the ten essential steps of opioid prescribing for chronic pain that can help mitigate any potential problems? A) Patient preference B) Trials of opioid monotherapy only
C) Diagnosis with an appropriate differential D) A single assessment of substance abuse risk
29. Which of the following is NOT one of the 5 A’s of monitoring chronic opioid response?
A) Analgesia B) Acceptance C) Affect (i.e., patient mood) D) Aberrant drug-related behaviors
A) DEA. B) FDA. C) CDC. D) SAMHSA.
30. For patients considered at medium risk for misuse of prescription opioids, urine drug testing should be completed every
A) 6 to 12 weeks. B) 3 to 6 months. C) 6 to 12 months. D) 1 to 2 years.
37. Which government agency is responsible for formulating federal standards for the handling of controlled substances? A) The DEA B) Institutes of Medicine C) Office of National Drug Control Policy D) U.S. Department of Health and Human Services 38. Patients who require ultra-high-dose opioids to control chronic pain should be restricted from the use of A) sedatives.
31. When using urine drug testing to monitor adherence and compliance, it is important to A) understand the limitations. B) always use manufacturer recommended testing frequency. C) aggressively confront patients with results suggesting non-use of a prescribed opioid. D) use immunoassay point-of-care results as the basis of important clinical decisions. 32. The U.S. Food and Drug Administration recommends that unused OxyContin tablets be disposed of by A) burning. B) flushing down the toilet. C) throwing in the garbage in a sealed container. D) sharing with a friend or relative with chronic pain.
B) benzodiazepines. C) muscle relaxants. D) All of the above
39. Nonpharmacologic approaches shown to be effective for the treatment of substance use disorder in patients with chronic pain include all of the following, EXCEPT: A) Mindfulness meditation
B) 12-step program involvement C) Cognitive-behavioral therapy D) Psychodynamic psychotherapy
33. An opioid should be safely discontinued with A) inadequate analgesia. B) resolution of the pain syndrome. C) significant aberrant medication use. D) All of the above
40. Which of the following is NOT an advantage of buprenorphine over methadone treatment of opioid use disorder in patients with chronic pain? A) Less stigma B) Higher retention rates C) Longer duration of action D) Greater safety margin in overdosew
34. Which of the following is an advantage of
abuse-deterrent opioid formulations utilizing aversive components? A) Very little risk for adverse events
B) Several approved FDA formulations exist C) May limit abuse by chewing or crushing the product D) Prevents accidental crushing or chewing in compliant patients
Course Code: MDMS1526
58
MDMS1526
Powered by FlippingBook